Study | Sample Size | Tumor Type | Duration of Follow-Up | Number (%) Requiring Enucleation for Tumor Recurrence by End of Follow-Up | Number (%) Requiring Enucleation for Treatment Side Effects by End of Follow-Up | Total Number (%) Requiring Enucleation | Predictors of Requiring Enucleation after Treatment |
Bergman et al. 2005 [29] | 579 eyes | Choroidal and ciliary body melanomas | 3 and 5 years | 60/579 (10.4%) at 3 years | 17/579 (2.9%) at 3 years | 106 patients enucleated total with cumulative incidence 16.8% | -- |
Sagoo et al. 2007 [10] | 37 patients | Circumpapillary choroidal melanoma | Mean 52 months, median 46 months | 3/37 (8.1%) | 4/37 (10.8%) | 7/37 (18.9%) | -- |
Sagoo et al. 2008 [11] | 141 patients | Juxtapapillary choroidal melanoma overhanging optic disc | Mean 56 months | 7/141 (5.0%) | 20/141 (14.2%) | 27/141 (19.1%) | -- |
Finger et al. 2010 [30] | 384 patients | Uveal melanomas treated with palladium-103 brachytherapy | Mean 47.2 months | -- | -- | 11/384 (2.9%) within 3 years | -- |
Gunduz et al. 2010 [12] | 24 patients | Choroidal melanoma treated with ruthenium brachytherapy alone | -- | -- | -- | 2/15 (13.3%) for tumors ≤5 mm, 1/9 (11.1%) for tumors >5 mm to <8 mm | -- |
Verschueren et al. 2010 [13] | 430 patients | Choroidal melanoma | Median 50 months | 10/430 (2.3%) | 7/430 (1.6%) | 17 (4.4%) | -- |